ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
21.74
+1.38 (6.78%)
At close: Oct 15, 2025, 4:00 PM EDT
21.52
-0.22 (-1.01%)
After-hours: Oct 15, 2025, 7:26 PM EDT
ACADIA Pharmaceuticals Revenue
ACADIA Pharmaceuticals had revenue of $264.57M in the quarter ending June 30, 2025, with 9.34% growth. This brings the company's revenue in the last twelve months to $1.02B, up 14.41% year-over-year. In the year 2024, ACADIA Pharmaceuticals had annual revenue of $957.80M with 31.85% growth.
Revenue (ttm)
$1.02B
Revenue Growth
+14.41%
P/S Ratio
3.56
Revenue / Employee
$1,557,928
Employees
654
Market Cap
3.67B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ACAD News
- 11 hours ago - Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 - Business Wire
- 9 days ago - ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish - Seeking Alpha
- 13 days ago - Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - Business Wire
- 21 days ago - Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - Benzinga
- 21 days ago - Acadia Pharmaceuticals' rare disease therapy fails late-stage trial - Reuters
- 21 days ago - Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint - Business Wire
- 4 weeks ago - Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology - Business Wire
- 5 weeks ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire